# Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer

> **NCT07112209** · NA · ENROLLING_BY_INVITATION · sponsor: **Zhujiang Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer

## Interventions

- **COMBINATION_PRODUCT:** Rezvilutamide combined with docetaxel

## Key facts

- **NCT ID:** NCT07112209
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-11-06
- **Primary completion:** 2027-06-10
- **Final completion:** 2027-11-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07112209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07112209, "Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07112209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*